Association of Concomitant PPI Use With Outcomes of Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer
JAMA Netw Open 2023 Jul 03;6(7)e2322915, H Kawachi, T Yamada, M Tamiya, Y Negi, Y Goto, A Nakao, S Shiotsu, K Tanimura, T Takeda, A Okada, T Harada, K Date, Y Chihara, I Hasegawa, N Tamiya, M Ishida, Y Katayama, K Morimoto, M Iwasaku, S Tokuda, T Kijima, K TakayamaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.